Iridex Corp IRIX
We take great care to ensure that the data presented and summarized in this overview for IRIDEX CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRIX
View all-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX1MShares$1.17 Million4.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$656,4820.0% of portfolio
-
Amh Equity LTD501KShares$586,3110.93% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny381KShares$445,9570.0% of portfolio
-
Geode Capital Management, LLC Boston, MA131KShares$153,4710.0% of portfolio
-
Ars Investment Partners, LLC110KShares$128,7700.02% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX70KShares$81,9000.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il67.7KShares$79,1540.0% of portfolio
-
Apexium Financial, LP65.7KShares$76,8630.01% of portfolio
-
Black Rock Inc. New York, NY56.5KShares$66,0790.0% of portfolio
Latest Institutional Activity in IRIX
Top Purchases
Top Sells
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Insider Transactions at IRIX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 29
2025
|
William M Moore |
BUY
Open market or private purchase
|
Direct |
19,710
+13.99%
|
$19,710
$1.21 P/Share
|
Apr 29
2025
|
Romeo R Dizon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,907
+17.82%
|
$3,907
$1.26 P/Share
|
Apr 28
2025
|
William M Moore |
BUY
Open market or private purchase
|
Direct |
290
+0.29%
|
$290
$1.24 P/Share
|
Apr 28
2025
|
Romeo R Dizon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,625
+22.47%
|
$2,625
$1.26 P/Share
|
Apr 28
2025
|
Patrick Mercer President and CEO |
BUY
Open market or private purchase
|
Direct |
7,500
+0.93%
|
$7,500
$1.3 P/Share
|
Apr 25
2025
|
Romeo R Dizon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
975
+28.26%
|
$975
$1.18 P/Share
|
Apr 24
2025
|
Patrick Mercer President and CEO |
BUY
Open market or private purchase
|
Direct |
46
+0.01%
|
$46
$1.15 P/Share
|
Apr 24
2025
|
Scott Shuda |
BUY
Open market or private purchase
|
Direct |
21,457
+14.21%
|
$21,457
$1.2 P/Share
|
Apr 24
2025
|
Romeo R Dizon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500
+25.0%
|
$500
$1.2 P/Share
|
Apr 23
2025
|
Romeo R Dizon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500
+33.33%
|
$500
$1.11 P/Share
|
Apr 23
2025
|
Beverly A Huss |
BUY
Open market or private purchase
|
Direct |
25,900
+21.85%
|
$25,900
$1.22 P/Share
|
Apr 22
2025
|
William M Moore |
BUY
Open market or private purchase
|
Direct |
10,000
+9.0%
|
$10,000
$1.08 P/Share
|
Apr 21
2025
|
William M Moore |
BUY
Open market or private purchase
|
Direct |
10,000
+9.89%
|
$10,000
$1.05 P/Share
|
Apr 21
2025
|
Romeo R Dizon Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$500
$1.05 P/Share
|
Nov 07
2024
|
Patrick Mercer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+33.71%
|
-
|
Jul 04
2024
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,073
-1.06%
|
$4,146
$2.07 P/Share
|
Jul 04
2024
|
David Bruce CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,788
-3.65%
|
$9,576
$2.07 P/Share
|
Jun 30
2024
|
David Bruce CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,098
-5.13%
|
$14,196
$2.16 P/Share
|
Jun 30
2024
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,123
-2.07%
|
$8,246
$2.16 P/Share
|
May 22
2024
|
Patrick Mercer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+37.57%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 320K shares |
---|---|
Open market or private purchase | 104K shares |
Payment of exercise price or tax liability | 18.1K shares |
---|